Skip to main content

Advertisement

Table 1 General characteristics of the study population

From: Serological assessment of gastric mucosal atrophy in gastric cancer

   Intestinal GC (n = 59) Diffuse GC (n = 59) Total (n = 118)
Age* (mean ± SD) 67.5 ± 12.5 years 62.2 ± 13.6 years 64.9 ± 13.3 years
Sex* (female) 42 71.2% 30 50.8% 72 61.0%
H. pylori (positive) 50 84.7% 49 83.1% 99 83.9%
CagA (positive in total) 39 66.1% 38 64.4% 77 65.3%
  (of H.pylori-positive)   78.0%   77.6%   77.8%
Localisation* Cardia 21 35.6% 13 22.0% 34 28.8%
  Corpus 21 35.6% 37 62.7% 58 49.2%
  Antrum 17 28.8% 9 15.3% 26 22.0%
  Proximal 30 50.8% 23 39% 53 44.9%
  Distal 29 49.2% 36 61% 65 55.1%
Atrophy* (positive) 33 55.9% 10 16.9% 43 36.4%
IM* (positive) 51 86.4% 35 59.3% 86 72.9%
PG1 (median, range) 81.9 (4.2-699.8) ng/ml 127.9 (5.3-877.5) ng/ml 103.3 (4.2-877.5) ng/ml
PG2 (median, range) 13.9 (3.2-173.5) ng/ml 13.1 (2.5-73.1) ng/ml 13.5 (2.5-173.5) ng/ml
PG-ratio* (median, range) 6.8 (0.4-25.8) 10.4 (1.6-26.7) 8.3 (0.4-26.7)
G17 (median, range) 13.8 (0.1-220.0) pM 12.8 (0.6-194.2) pM 13.4 (0.1-220.0) pM
  1. Serum parameters are illustrated by median and range. Patients were regarded as "positive" for atrophy and IM if the Sydney-scaled degree of the mucosal alteration was ≥ 1. Significant differences between intestinal and diffuse type GC are marked with an asterisk (*) applying a two-sided significance level of p < 0.05.